International Symposium of Hemotherapy & Cell Therapy

Vimal is a Process Development Scientist in Dr. Steven Feldman’s group at the Stanford Center for Cancer Cell Therapy focusing on developing CRISPR knock-in platforms for non-viral CAR-T manufacturing. Prior to working on non-viral platforms, Vimal worked on the process development of Allogeneic Hematopoietic Stem Cell Transplants and donor derived T-allo10 Tr1 cell therapies at Stanford’s cGMP Laboratory of Cell & Gene Medicine.